Dr. Scangos has decades of experience building and leading biopharmaceutical companies, most recently as the founding President, CEO (2016 – 2023) and as a continuing board member of Vir Biotechnology. Under his leadership, Vir delivered life-saving therapies for Ebola and COVID-19 to millions of patients while also building a pipeline spanning five therapeutic areas.
Prior to Vir, Dr. Scangos served as CEO and a board member of Biogen for six years. Previously, he served as President and CEO of Exelixis for 14 years. He was also former President of Bayer Biotechnology, and the former Chair of Anadys Pharmaceuticals, PhRMA, and California Healthcare Institute. He was also a member of the Board of Directors of the Global Alliance for TB Drug Development. Prior to joining the industry, he was a Professor of Biology at Johns Hopkins University.
Dr. Scangos has been highly recognized for his leadership in the biotech industry. He was named “Businessperson of the Year” by Fortune in 2014 and 2015, and also named one of “The Best Performing CEOs in the World” by Harvard Business Review for three consecutive years (2014 – 2016).
Dr. Scangos is currently a Venture Partner at ARCH Venture Partners, and also serves on the boards of Agilent Technologies, Inc., Voyager Therapeutics, Inc., Octave Bioscience, Rezo Therapeutics and Life Sciences Cares.
Dr. Scangos received his B.A. in biology from Cornell University and a Ph.D. in microbiology from the University of Massachusetts. After post-doctoral work at Yale, he joined the faculty at Johns Hopkins University, where he currently holds an appointment as Adjunct Professor.